Patents Assigned to University of Connecticut Health Center
  • Publication number: 20170100455
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Application
    Filed: May 16, 2016
    Publication date: April 13, 2017
    Applicant: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Patent number: 9566348
    Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: February 14, 2017
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Patent number: 9352019
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: May 31, 2016
    Assignee: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Patent number: 9248172
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: February 2, 2016
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Zihai Li
  • Publication number: 20150231200
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Application
    Filed: April 27, 2015
    Publication date: August 20, 2015
    Applicant: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Publication number: 20150118253
    Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 30, 2015
    Applicant: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Patent number: 8877204
    Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: November 4, 2014
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Publication number: 20140107391
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Zihai Li
  • Publication number: 20120021996
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicant: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Zihai Li
  • Publication number: 20120021997
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicant: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Zihai Li
  • Patent number: 7666581
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of infectious diseases, and cancers. The methods of the invention comprises complexing a population of antigenic proteins or antigenic peptides derived from antigenic cells or viral particles to one or more different heat shock proteins in vitro. The population or the protein preparation used to produce the antigenic peptides comprises at least 50% of the different proteins or at least 50 different proteins of the antigenic cells or viral particles. Methods for making antigenic peptides comprise digesting a protein preparation of antigenic cells, a cellular fraction thereof, or of viral particles with one or more proteases, or exposing the protein preparation to ATP, guanidium hydrochloride, and/or acidic conditions.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: February 23, 2010
    Assignee: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Patent number: 7449557
    Abstract: The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: November 11, 2008
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Patent number: 7186515
    Abstract: The present invention relates to the use of alpha (2) macroglobulin (“?2M”) receptor as a heat shock protein receptor, cells that express the ?2M receptor bound to an HSP, and antibodies and other molecules that bind the ?2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that modulate the interaction of an HSP with the ?2M receptor, and methods for using compositions comprising ?2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: March 6, 2007
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Patent number: 7179462
    Abstract: The present invention relates to the use of alpha (2) macroglobulin (“?2M”) receptor as a heat shock protein receptor, cells that express the ?2M receptor bound to an HSP, and antibodies and other molecules that bind the ?2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the ?2M receptor, and modulate the interaction of the ?2M receptor with its ligand, such as HSPs, and methods for using compositions comprising ?2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: February 20, 2007
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Publication number: 20070003555
    Abstract: The present invention relates to compositions and methods for the use of natural and recombinant p95 forms and fragments as heat shock protein binding proteins. The invention is based, in part, on the Applicant's discovery that a p95 can be recombinantly expressed. The present invention also relates to CD91 polypeptide fragments that comprise at least p95 and additional contiguous sequence from domain II, III, and IV of CD91.
    Type: Application
    Filed: October 7, 2003
    Publication date: January 4, 2007
    Applicants: UNIVERSITY OF CONNECTICUT HEALTH CENTER, ANTIGENICS, INC.
    Inventor: Kenneth LeClair
  • Patent number: 7132109
    Abstract: The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which are then introduced into a subject in conjunction with a vaccine. The HSPs used in the methods of the invention can be unbound or can be covalently or noncovalently bound to a peptide that is unrelated to the vaccine. The subject is preferably mammalian, and most preferably human. It is shown by way of example herein that HSPs induces secretion of cytokines and surface expression of antigen-presenting and co-stimulatory molecules. The invention also encompasses methods of treatment and prevention of cancer and infectious diseases in a subject.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: November 7, 2006
    Assignee: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Publication number: 20060165710
    Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
    Type: Application
    Filed: February 20, 2004
    Publication date: July 27, 2006
    Applicant: UNIVERSITY OF CONNECTICUT HEALTH CENTER
    Inventors: Pramod Srivastava, Robert Binder
  • Patent number: 6984389
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: January 10, 2006
    Assignee: University of Connecticut Health Center
    Inventor: Zihai Li
  • Patent number: 6797480
    Abstract: The present invention relates to receptors for heat shock proteins (HSPs), such as gp96, Hsp70 and Hsp90. The heat shock receptor is associated with the cell membranes of a subset of antigen presenting cells, such as macrophages and dendritic cells. The present invention relates to the use of the heat shock protein receptor positive cells, heat shock protein receptor protein, and heat shock protein receptor genes in methods for screening a molecule for the ability to modulate heat shock protein levels or activities.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: September 28, 2004
    Assignee: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Publication number: 20040022796
    Abstract: The present invention provides a method of improving or prolonging a subject's immune response to a vaccine composition comprising heat shock protein (HSP)-peptide complexes or alpha-2-macroglobulin (&agr;2M)-peptide complexes (hereinafter “HSP/&agr;2M vaccine composition”). The HSP-peptide complexes or &agr;2M-peptide complexes of the vaccine composition comprise HSP(s) or &agr;2M complexed to a component against which an immune response is desired to be induced. In particular the invention is directed to methods of improving or prolonging a subject's immune response comprising administering an HSP/&agr;2M vaccine composition in conjunction with a preparation comprising HSP or &agr;2M, alone or complexed to a peptide that is not the component against which an immune response is desired to be induced (hereinafter “HSP/&agr;2M preparation”), i.e., the HSP/&agr;2M preparation does not display the immunogenicity of the component.
    Type: Application
    Filed: May 1, 2003
    Publication date: February 5, 2004
    Applicant: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava